In the War Against Infections.

Article

Zyvox Becomes the Next Combatant

ROCKVILLE, MD-The first antibacterial drug in a new class of synthetic drugs, Zyvox, has been approved by the Food and Drug Administration (FDA) for a number of uses:

1. To treat infections associated with vancomycin-resistant Enterococcus faecium (VREF), including cases with bloodstream infection.

2. To treat nosocomial pneumonia and complicated skin and skin structure infections, including cases due to methicillin-resistant Staphylococcus aureus (MRSA).

3. To treat community-acquired pneumonia and uncomplicated skin and skin structure infections.

Developed and manufactured by Pharmacia and Upjohn, Zyvox is the first drug in over 40 years to be introduced to the US market for treatment of MRSA infections. Side effects reported in the clinical studies were headache, nausea, diarrhea, and vomiting. The most important laboratory test change was a decrease in platelet counts. Zyvox may interact with other drugs that contain pseudoephedrine or phenylpropanolamine, such as over-the-counter cold remedies, and raise a patient's blood pressure.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
Jill Holdsworth, MS, CIC, FAPIC, NREMT, CRCST, CHL, an infection preventionist from Atlanta, Georgia.  (Photo credit: Tori Whitacre Martonicz)
"Top 5" in a blue ribbon  (Adobe Stock 235182652 by Evgeny)
Bug of the Month
© 2025 MJH Life Sciences

All rights reserved.